

Diagnosis and Management of Chronic Pancreatitis

A Review

Vikesh K. Singh, MD, MSc; Dhiraj Yadav, MD, MPH; Pramod K. Garg, MD

IMPORTANCE Chronic pancreatitis (CP) is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42 to 73 per 100 000 adults in the United States.

OBSERVATIONS Both genetic and environmental factors are thought to contribute to the pathogenesis of CP. Environmental factors associated with CP include alcohol abuse (odds ratio [OR], 3.1; 95% CI, 1.87-5.14) for 5 or more drinks per day vs abstainers and light drinkers as well as smoking (OR, 4.59; 95% CI, 2.91-7.25) for more than 35 pack-years in a case-control study involving 971 participants. Between 28% to 80% of patients are classified as having "idiopathic CP." Up to 50% of these individuals have mutations of the trypsin inhibitor gene (*SPINK1*) or the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. Approximately 1% of people diagnosed with CP may have hereditary pancreatitis, associated with cationic trypsinogen (*PRSS1*) gene mutations. Approximately 80% of people with CP present with recurrent or chronic upper abdominal pain. Long-term sequelae include diabetes in 38% to 40% and exocrine insufficiency in 30% to 48%. The diagnosis is based on pancreatic calcifications, ductal dilatation, and atrophy visualized by imaging with computed tomography, magnetic resonance imaging, or both. Endoscopic ultrasound can assist in making the diagnosis in patients with a high index of suspicion such as recurrent episodes of acute pancreatitis when imaging is normal or equivocal. The first line of therapy consists of advice to discontinue use of alcohol and smoking and taking analgesic agents (nonsteroidal anti-inflammatory drugs and weak opioids such as tramadol). A trial of pancreatic enzymes and antioxidants (a combination of multivitamins, selenium, and methionine) can control symptoms in up to 50% of patients. Patients with pancreatic ductal obstruction due to stones, stricture, or both may benefit from ductal drainage via endoscopic retrograde cholangiopancreatography (ERCP) or surgical drainage procedures, such as pancreaticojejunostomy with or without pancreatic head resection, which may provide better pain relief among people who do not respond to endoscopic therapy.

CONCLUSIONS AND RELEVANCE Chronic pancreatitis often results in chronic abdominal pain and is most commonly caused by excessive alcohol use, smoking, or genetic mutations. Treatment consists primarily of alcohol and smoking cessation, pain control, replacement of pancreatic insufficiency, or mechanical drainage of obstructed pancreatic ducts for some patients.

JAMA. 2019;322(24):2422-2434. doi:10.1001/jama.2019.19411

[+ Supplemental content](#)

[+ CME Quiz at jamanetwork.com/learning](#)

Author Affiliations: Division of Gastroenterology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland (Singh); Division of Gastroenterology & Hepatology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Yadav); Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India (Garg).

Corresponding Author: Vikesh K. Singh, MD, MSc, Division of Gastroenterology, Johns Hopkins University School of Medicine, 1830 E Monument St, Room 428, Baltimore, MD 21287 (vsingh1@jhmi.edu).

Section Editors: Edward Livingston, MD, Deputy Editor, and Mary McGrae McDermott, MD, Deputy Editor.

Chronic pancreatitis (CP) is a chronic progressive disease with an annual incidence of 5 to 8 and prevalence of 42 to 73 cases per 100 000 adults in the United States.¹⁻³ Prevalence rates varying from 36 to 125 per 100 000 population have been reported from Japan, China, and India, of which India has the highest prevalence.^{4,5}

Chronic pancreatitis is characterized by fibrosis and inflammation of the pancreas in individuals with genetic, environmental, and other risk factors such as hypertriglyceridemia. Chronic pancreatitis is characterized by pancreatic atrophy, fibrosis, ductal strictures and distortion, calcifications, dysplasia, exocrine insufficiency and diabetes, and chronic pain.⁶

This review summarizes current evidence regarding risk factors, pathophysiology, clinical features, diagnostic evaluation, treatment, and prognosis of CP.

Methods

We searched PubMed for relevant English-language articles published from January 1, 2000, to July 1, 2019. Search terms included *chronic pancreatitis* and each of the following: *epidemiology, genetic variants, genetic mutations, genetic polymorphisms, risk factors, acute pancreatitis, recurrent acute pancreatitis, pathophysiology, pain, steatorrhea, weight loss, malabsorption, exocrine insufficiency, diabetes, treatment, management, neuromodulators, pancreatic enzymes, antioxidants, medical management, endoscopy, endoscopic retrograde cholangiopancreatography [ERCP], extracorporeal shock wave lithotripsy [ESWL], endoscopic ultrasound [EUS], surgery, pancreaticojejunostomy, total pancreatectomy, and islet autotransplantation*. Case reports and case series were excluded.

Observations

The literature search yielded 28 686 articles, from which 584 randomized clinical trials, 325 meta-analyses, 484 systematic reviews, and 126 guidelines were selected for further review. A total of 637 articles relevant to clinical chronic pancreatitis were included after excluding studies on acute pancreatitis, review articles, animal studies, duplicate articles, and protocols.

Risk Factors

Alcohol abuse is the most common etiology of CP and is diagnosed in 42% to 77% of patients. Idiopathic CP is the second most common type and affects 28% to 80% of people with the condition. In a multicenter study involving 416 patients with CP and 555 participants without it (spouses, family members, or unrelated persons seen at participating institutions), the odds of self-reported alcohol consumption of 5 or more drinks a day were 3.1-fold greater among those with CP than among those without it.⁷ In an observational study involving 17 905 participants from the Copenhagen City Heart Study,⁸ which had a median follow-up of 20.2 years, the relative risk (RR) of CP increased by 2.7 (95% CI, 1.1-6.6) among those who consumed at least 35 drinks and by 3.3 (95% CI, 1.3-8.3) among those who consumed 48 or more drinks a week compared with those who did not drink (Table 1).

Smoking is associated with risk of CP in a dose-dependent fashion. The Copenhagen observational study⁹ also found that compared with never smokers, the RR of having CP among those who smoked between 15 and 24 cigarettes a day was 2.0 (95% CI, 1.0-4.1) and was 3.3 (95% CI, 1.5-7.3) among those who smoked 25 or more cigarettes a day (1 cigarette is approximately the equivalent of 1 g). In the US study involving 416 people with CP and 555 without it, the odds of having CP among those smoking 12 to 35 pack-years was 2.15 (95% CI, 1.46-3.17) and among those smoking more than 35 pack-years was 4.59 (95% CI, 2.91-7.25) compared with never smokers (Table 1). Smoking may be associated with other risk factors (such as alcohol consumption) in a synergistic manner.⁷ In a recent multicenter US study involving 1159 patients, the 3 most common etiologies identified in 911 white participants with CP were alcohol (42%), idiopathic (28%), and genetic mutations (10%). Among 248 black patients, the most common etiologies were alcohol (77%), idiopathic (12.9%), and genetic (1.6%) causes.²⁰ In a study involving 2037 patients with CP from China, 19.8% had alcoholic CP and 80.2% had idiopathic CP.²¹ In 411 patients with CP from India, 58.9% had idiopathic CP and 38.2% had alcoholic CP.¹³

Variants in several genes are associated with idiopathic CP (Table 1). Among 134 patients from the United States, 88 pathogenic genetic variants were found in the cationic trypsinogen 1 (*PRSS1* [HGNC 9475]), cystic fibrosis transmembrane conductance regulator (*CFTR* [HGNC 1884]), serine protease inhibitor Kazal type 1 (*SPINK1* [HGNC 11244]), and chymotrypsin C (*CTRC* [HGNC 2523]) genes in 64 patients (47.8%) with idiopathic CP.²² In a study involving 715 Chinese patients with idiopathic CP, pathogenic genetic variants involving these genes were found in 57.1% of patients compared with only 5.9% of controls (odds ratio [OR], 16.1; $P < .001$).¹¹ Similarly, mutations in the *SPINK1* and *CFTR* genes were present in 42% of Indian patients with idiopathic CP vs 4% of controls ($P < .001$). Such mutations were present in 39.8% of Chinese patients and 17% of Indian patients with alcoholic CP. Mutations in the *PRSS1* gene were associated with hereditary pancreatitis with an autosomal dominant inheritance but only accounted for approximately 1% of all CP.

Other less common risk factors include hypercalcemia (generally due to a parathyroid adenoma),²³ hypertriglyceridemia, autoimmune disorders (eg, celiac disease, inflammatory bowel disease), and uncommon anatomic abnormalities, such as an annular pancreas. The role of pancreas divisum and sphincter of Oddi dysfunction as causes of idiopathic CP are controversial.

Chronic pancreatitis affects patients of all ages, and the affected age group depends on the etiology. Patients with CP due to alcohol typically present between the ages of 40 and 60 years; two-thirds of patients are men; and black patients have CP more commonly than do white patients. Patients with CP due to genetic mutations typically present between the ages of 10 and 40 years, and both sexes are affected nearly equally. Patients diagnosed with idiopathic CP have a bimodal presentation. A study involving 66 patients with idiopathic CP reported that the median age at presentation for early-onset CP was 19 years; late-onset CP, 56 years.²⁴

Pathophysiology

Chronic pancreatitis develops slowly, starting with cellular injury, followed by inflammation and fibrosis. The pathophysiological processes in CP involve the acinar cells, the predominant site of initial injury or stress, leading to an inflammatory cascade.

Cellular Injury

Acinar cells, which constitute the majority of pancreatic volume, synthesize and secrete digestive enzymes into the pancreatic ductal system. Alcohol causes acinar cell injury due to its metabolites, such as acetaldehyde following oxidative metabolism, and fatty acid ethyl esters generated by nonoxidative metabolism.²⁵ The adverse effects of alcohol on pancreatic ductal and pancreatic stellate cells also contribute to the pathogenesis.^{26,27} Smoking contributes to acinar cell injury due to its toxic metabolite nicotine derived nitrosamine ketone.²⁸ Genetic mutations associated with CP can cause cellular injury either in a trypsin-dependent (ie, trypsin activation involved in pathophysiology) or trypsin-independent (ie, trypsin activation not involved in pathophysiology) manner (Table 1). Mutations or polymorphisms lead to premature or increased activation of trypsinogen due to either gain-of-function variants in the cationic trypsinogen gene (*PRSS1*) or loss-of-function variants in genes such as *SPINK1* and *CTRC* that code for trypsin-inactivating proteins.^{13,29,30} Increased intracellular trypsin activation leads to cellular injury through mechanisms such as endoplasmic reticulum stress, oxidative stress, and impaired autophagy.³¹⁻³³ Trypsin-independent mutations in *CFTR*, carboxypeptidase A1 (*CPA1* HGNC 2296), and claudin 2 (*CLDN2* [HGNC 2041]) genes cause injury due to different mechanisms.^{15-17,34} Cystic fibrosis transmembrane conductance regulator dysfunction most likely affects bicarbonate secretion by the pancreatic ductal cells.²⁷ Individual susceptibility to CP due to excessive alcohol use may depend on these aforementioned genetic variants, those coding for alcohol metabolizing enzymes or other yet unknown genes.^{35,36} Low ORs of 1.4 and moderate ORs of 5.3 for most genetic variants suggest that CP is a complex disorder that is due to both genetic and environmental causes (eTable in the Supplement).

Inflammation

Acinar cell injury and death result in inflammation possibly related to release of damage-associated molecular patterns (DAMPs) as

Table 1. Risk Factors for Chronic Pancreatitis

Risk Factor	Frequency of Risk Factor in Chronic Pancreatitis vs Control Patients	(95% CI) Odds Ratio	Relative Risk
Environmental factors ^a			
Alcohol (drinks per d), drinkers vs controls, No. (%) ⁷			
Moderate	89 (21.4) vs 132 (23.8)	0.81 (0.56-1.18)	
Heavy	54 (13) vs 74 (13.3)	0.83 (0.54-1.29)	
Very heavy (≥5)	102 (24.5) vs 30 (5.4)	3.10 (1.87-5.14)	
Drinks/wk, No. (%) / Total ⁸			
1-6	25 (0.4)/6100 vs 18 (0.4)/3901		1.2 (0.7-2.3)
7-13	17 (0.5)/3543 vs 18 (0.4)/3901		1.2 (0.6-2.4)
14-20	12 (0.6)/1871 vs 18 (0.4)/3901		1.5 (0.7-3.2)
21-34 ^b			1.3 (0.6-3.1)
35-48 ^b			2.7 (1.1-6.6)
>48 ^b			3.3 (1.3-8.3)
Smoking pack-years, smokers vs controls, No. (%) ⁷			
<12	70 (16.8) vs 104 (18.7)	1.34 (0.9-2.01)	
12-35	103 (24.8) vs 98 (17.7)	2.15 (1.46-3.17)	
>35	111 (26.7) vs 51 (9.2)	4.59 (2.91-7.25)	
Smoking ⁹			
Former	13 (0.4)/3027 vs 11(0.2)/3745		0.9 (0.4-2.0)
1-14 g/d	18 (0.3)/4793 vs 11 (0.2)/3745		1.1 (0.5-2.3)
15-24 g/d	34 (0.7)/4793 vs 11(0.2)/3745		2.0 (1.0-4.1)
≥25 g/d	34 (0.7)/4793 vs 11 (0.2)/3745		3.3 (1.5-7.3)
Genetic variants, No. (%) / total			
Trypsin dependent			
<i>PRSS1</i>			
White ¹⁰	55 (8.3)/660 vs 0 (0)/1758	322.4 (19.8-5230)	
Chinese ¹¹	55(7.6)/715 vs 25 (2.1)/1196	3.9 (2.4-6.3)	
<i>SPINK1</i> (N34S)			
White ¹²	23 (40.3)/57 vs 3 (1.5)/190	42.2 (11.5-226)	
Indian ¹³	48 (42.4)/113 vs 4 (4.0)/100	32.5 (10.9-127.9)	
<i>CTRC</i>			
White ¹⁰	22 (4.0)/546 vs 13 (0.8)/1667 (0.8)	5.3 (2.7-10.7)	
Indian ¹⁴	71 (12.2)/584 vs 22 (3.7)/598	3.6 (2.2-5.9)	
Trypsin-independent			
<i>CFTR</i>			
White ¹⁰	103 (15.3)/660 vs 112 (6.4)/1758	2.7 (2-3.6)	
Indian ¹³	3 (2.6)/113 vs 3 (0.3)/900	8.2 (1.1-61.4)	
<i>CPA1</i>			
White ¹⁵	29 (3.1)/944 vs 5(0.1)/3938	24.9 (9.5-82.6)	
Indian ¹⁵	5 (2.2)/230 vs 0/264	2% Risk allele vs 0 in controls	
Japanese ¹⁵	5 (2.0)/247 vs 0/341		
<i>CLDN2</i> (<i>MORC4</i>), allele frequency, % of total ^c			
White ¹⁶	248 (36.7)/676 vs 1176 (26.1)/4507	1.61 (P = 2.4 × 10 ⁻²¹)	
Indian ¹⁷	353 (80)/441 vs 762 (59.6)/1279	2.7 (2.1-3.6)	
CEL (not replicated in nonwhite patients) ¹⁸	42 (3.7)/1122 vs 30 (0.7)/4152	5.2 (3.2-8.5)	
Autoimmune ^d			
Celiac disease ¹⁹	37 (0.2)/ 14 239 vs 13 (0.01)/ 69 381		19.8 (9.2-42.8)

Abbreviations: *CFTR*, cystic fibrosis transmembrane conductance regulator; *CLDN2*, claudin 2; *CPA1*, carboxypeptidase A1; *PRSS1*, serine protease 1; *SPINK1*, serine peptidase inhibitor Kazal type 1.

^a Drinking categories are based on the maximum drinking period over a lifetime: abstainers are those who have never imbibed alcohol or had fewer than 20 drinks in a lifetime; light drinkers, 3 or fewer drinks per week; moderate drinkers, from 4 to 7 drinks per week for women and 4 to 14 drinks per week for men; heavy drinkers, from 8 to 34 drinks per week for women and 15 to 34 drinks per week in men; and very heavy drinkers, at least 35 drinks per week for both sexes. The reference group for comparison were abstainers or light drinkers.

^b The number of women in individual categories of drinking was not stratified for more than 20 drinks per week.

^c For rs12688220.

^d Precise odd ratios and relative risks are not available for inflammatory bowel disease, hypertriglyceridemia, hypercalcemia, annular pancreas, but multiple studies have shown an associated with chronic pancreatitis.

seen in acute alcoholic pancreatitis.³⁷ Nuclear factor κ B (NF- κ B) plays a key role in initiating the inflammatory cascade.³⁸ Inflammation is promoted primarily by innate immune cells, predominantly macrophages.³⁹ The role of adaptive immune cells is not clear. Oxidative stress has been shown to be involved in the pathophysiology of CP.⁴⁰

Fibrosis

Pancreatic stellate cells normally exist in a quiescent state and become activated upon stimulation. Activated pancreatic stellate cells are important mediators of chronic inflammation and fibrosis in CP.⁴¹ Transforming growth factor β is the most important cytokine associated with fibrosis.⁴² Histopathological characteristics of CP include interlobular and intralobular fibrosis, acinar cell loss, distorted architecture, and dilated ducts.⁴³

Development of CP

A widely accepted theory is that an acute event causes significant acinar cell stress or injury, which precipitates a clinically evident episode of acute pancreatitis. Patients with prior acute pancreatitis are susceptible to recurrent episodes due to either chronic toxic insults or genetic susceptibility. Most recurrent pancreatitis episodes present with epigastric pain. Repeated pancreatic parenchymal injury and chronic inflammation result in fibrosis. Fibrosis involving the pancreatic ducts leads to focal duct strictures with dilatation of the duct proximal to the obstruction. Calculi form secondary to stasis of secretions and calcification of protein plugs. Ductal obstruction and repeated injury lead to parenchymal loss and pancreatic atrophy. The necrosis-fibrosis hypothesis of CP pathophysiology consists of progression from acute pancreatitis to recurrent acute pancreatitis to CP.^{44,45} In some patients, however, features of advanced disease such as calcifications or marked ductal changes are present at the initial presentation.⁴⁶ In patients without antecedent clinically manifest acute pancreatitis, the progression to CP is assumed to be via asymptomatic subclinical parenchymal injury and inflammation. The reasons for the 2 different types of presentations (symptomatic vs asymptomatic) are unknown but could be related to acuity and degree of inflammation or to a patient's pain threshold.⁴⁷

Another hypothesis is the obstructive hypothesis, in which hypersecretion and protein precipitation lead to protein-plug formation in the pancreatic ducts that calcify and lead to obstruction resulting in acinar cell dysfunction and atrophy.⁴⁸ The mechanism of protein precipitation is unclear but could involve dysfunction of *CFTR* channels either by alcohol and its metabolites or *CFTR* gene mutations, causing impaired bicarbonate secretion resulting in intraductal acidification.^{27,49} The *CFTR* is a selective ion channel involved in chloride and bicarbonate transport that produces bicarbonate-rich alkaline fluid in pancreatic ducts, which helps in solubilization of proteins. The flow of luminal content is thus impaired in *CFTR* dysfunction leading to the formation of intraductal protein plugs.

Sphincter of Oddi dysfunction was previously thought to be a cause of pancreatitis. However, 2 studies, one a prospective cohort of 201 patients⁵⁰ and the other a randomized trial of 69 patients,⁵¹ reported acute pancreatitis recurrence rates of 55% over a median follow-up of 37 months and 50% to 77% over a median follow-up of 78 months, respectively, after endoscopic therapy for idiopathic recurrent acute pancreatitis due to suspected sphincter of Oddi

Table 2. Prevalence of Signs, Symptoms, and Complications of Chronic Pancreatitis

Symptoms	Prevalence in Chronic Pancreatitis, %
No pain ⁵³⁻⁵⁵	6-24
Abdominal pain ⁵³⁻⁵⁷	60-94
Pain pattern types	
A, Usually pain free, but episodes of mild to moderate pain ^{53,54}	9-13
B, Constant mild to moderate pain ^{53,54}	8-34
C, Usually free of abdominal pain, but episodes of severe pain ^{53,54}	19-51
D, Constant mild to moderate pain plus episodes of severe pain ^{53,54}	45
E, Constant severe pain ^{53,54}	6
Pain frequency	
Intermittent (types A and C) ⁵⁸	32
Constant (types B, D, and E) ⁵⁸	53
Pain severity	
Mild-moderate (types A and B) ⁵⁸	18
Severe (types C, D, and E) ⁵⁸	67
Complications	
Any acute pancreatitis ^{46,55}	42-50
Recurrent acute pancreatitis ^{55,57}	31-34
Exocrine insufficiency at diagnosis ^{24,55}	10-13
Nutritional manifestations	
Low BMI (underweight, <18 kg/m ²) ⁵⁹	8
Fat soluble vitamin deficiency	
Vitamin A (<30 μ g/dL) ⁵⁹	25
Vitamin D (<10 ng/mL) ^{59,60}	21-38
Vitamin E (<5.7 mg/L) ⁵⁹	17
Osteopenia ⁶¹	29-52
Osteoporosis ⁶¹	17-32
Fracture ⁶²⁻⁶⁴	5-21
Endocrine insufficiency at diagnosis ^{55,65}	10-33

Abbreviation: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared.


SI conversion factors: To convert vitamin A from μ g/dL to μ mol/L, multiply by 0.349; vitamin D from ng/mL to nmol/L, multiply by 2.496; and vitamin E from mg/L to μ mol/L multiply by 2.32.

dysfunction. The high recurrence rates of acute pancreatitis reported in these studies as well as overall pain relief rates at 1 year of only 28% in a sham controlled trial involving 201 patients undergoing endoscopic therapy for suspected sphincter of Oddi dysfunction⁵² have led to declines in the use of invasive therapies for managing this condition.

Mechanism of Pain in CP

Abdominal pain is clinically the most significant feature of CP, but the etiology is poorly understood. Pancreatic inflammation is associated with the release of inflammatory molecules from damaged cells, activating both mast cells and platelets and resulting in transmission of nociceptive signals to the pain centers of the brain via dorsal root ganglia and dorsal horn of the spinal cord. Patterns of pain vary based on the temporal nature of CP and severity (Table 2).⁵⁸

Figure 1. Diagnosis and Treatment Algorithm for Chronic Pancreatitis



This algorithm has not been validated in randomized trials.

Recurrent pancreatic inflammation associated with recurrent pancreatitis results in episodic acute abdominal pain. Patients who develop ductal obstruction due to stones, stricture, or both may have continuous pain and recurrent episodes of pain with both ductal hypertension, ie, increased pressure due to ductal obstruction and inflammation possibly playing a role. Long-term continuous pain may be due to structural complications such as an inflammatory head mass, pseudocyst, or pancreatic cancer.⁶⁶ However, many patients with continuous pain do not have structural complications or evidence of inflammation. These patients may have neuropathic pain. Pancreatic nociceptive afferent injury over time can result in peripheral sensitization, central sensitization, or both, characterized by neuronal hyperresponsiveness,

which can result in a continual state of pain independent of peripheral nociceptive input.⁶⁷ Among patients who experience chronic pain, histological changes in the pancreas including an increase in the density and volume of the intrapancreatic nerves and structural changes in the brain such as alterations in cerebral cortical thickness, suggest that pancreatic and central neural changes occur over long-term follow-up.⁶⁸ Sensitization manifests as hyperalgesia and allodynia. Central sensitization is associated with reduced efficacy of invasive endoscopic and surgical treatments directed at the pancreas.⁶⁹ Pain resolves among some patients with both long-standing CP and an atrophic pancreas. One study involving 288 patients reported that 57% were pain free at the 5-year follow-up.⁷⁰

Table 3. Sensitivity, Specificity, Advantages, and Disadvantages of Diagnostic Tests for Chronic Pancreatitis

Diagnostic Study	Findings	% (95% CI) ^a		Advantages	Disadvantages	Recommendation
		Sensitivity	Specificity			
CT	Calcifications, marked ductal dilation, atrophy,	75 (66-83)	91 (81-96)	High sensitivity for calcifications High sensitivity for diagnosing CP complications	Suboptimal visualization of pancreatic duct Low sensitivity and specificity for early CP	First-line diagnostic imaging study, best for calcification and marked dilation of the pancreatic duct
MRI with MRCP with or without secretin	Parenchymal changes (atrophy, T1 signal intensity) Ductal changes (main pancreatic duct dilation, stricture or irregularity as well presence of abnormal side branches) Secretin during MRCP stimulates pancreatic secretion, which causes duodenal filling that can be assessed quantitatively for exocrine function	78 (69-85)	96 (90-98)	Secretin-enhanced MRCP has higher sensitivity and specificity than CT for changes of the main pancreatic duct including dilation and strictures as well as changes in the side branches No ionizing radiation	Low sensitivity for small ductal calculi and parenchymal calcifications Lack of widespread availability	If CT shows normal results but suspicion of CP is high, MRI with MRCP should be obtained to evaluate for ductal changes
EUS	Four parenchymal criteria (lobularity, cyst, hyperechoic foci, and hyperechoic strands) Five ductal criteria (dilation, irregularity, calcifications or stones, echogenic duct wall margins, and side branch)	81 (70-89)	90 (82-95)	High sensitivity Less invasive than ERCP Allows for tissue sampling	Low specificity High interobserver variability Not all criteria carry similar importance	If CT and MRI are normal and the suspicion for CP is still high, especially in patients with RAP, EUS should be performed

Abbreviations: CP, chronic pancreatitis; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; RAP, recurrent acute pancreatitis.

^a Sensitivity and specificity for CT, MRI-MRCP, and EUS were adopted from Issa et al.⁷⁶

Clinical Presentation


Characteristic symptoms, signs, and complications in patients with CP are shown in Table 2. Abdominal pain is present in more than 80% of patients with CP.⁵⁸ Although classically reported as a dull pain localized to the epigastrium with radiation to the back that worsens after meals, the character, pattern, and severity of pain can vary.⁷¹ The presence and characteristics of abdominal pain do not always correlate with the extent of pathological changes of CP.^{58,72,73} Patients may experience nausea, vomiting, or both, especially during exacerbations of pain attacks or during episodes of acute pancreatitis. Approximately 70% of adult patients with CP have at least 1 episode of acute pancreatitis and 50% have recurrent acute pancreatitis during the clinical course of CP.⁵⁴ Patients with early-onset CP (ie, symptom onset before age 35 years) and those with alcohol etiology are more likely to have abdominal pain and at least 1 episode of acute pancreatitis. The clinical manifestations of exocrine insufficiency are related to maldigestion, which can result in steatorrhea (oily stools), weight loss, and fat-soluble vitamin deficiencies. In a meta-analysis of 10 studies consisting of 513 patients with CP who had undergone dual-energy x-ray absorptiometry, the pooled estimates for osteoporosis were 23.4% (95% CI, 16.6%-32%) and for osteopenia, 39.8% (95% CI, 29.1%-51.6%).⁶¹ During a 10-year period (1998-2008), the period prevalence of low trauma fractures (vertebrae, hip, and wrist) identified by diagnosis codes in patients with a diagnosis of CP was significantly greater than did controls (4.82%, 154 of 3192 vs 1.13%, 16 208 of 1 436 699) and patients with Crohn disease (3%, 182 of 6057). When compared with controls, patients with CP were at 2.7 times greater risk and those

with Crohn disease were at 1.7 times greater risk of fractures. The risk of fractures in patients with CP was similar to other gastrointestinal diseases, such as cirrhosis, celiac disease and history of gastrectomy.⁶³ A recent systematic review of 15 studies involving 8970 patients reported a prevalence of new onset diabetes of 15% within 36 months and 33% after 60 months after a diagnosis of CP.⁷⁴

Assessment and Diagnosis

A contrast-enhanced computed tomographic (CT) scan is an initial diagnostic test and should be performed for all patients with suspicion of CP (Figure 1). Amylase and lipase are helpful for diagnosing acute pancreatitis but not CP. Computed tomographic scans have an overall sensitivity of 75% for CP (95% CI, 66%-83%). The presence of either calcifications, marked pancreatic ductal changes, or both of these findings on a CT scan establishes the diagnosis of CP. In patients with a low probability of disease, eg, those with atypical symptoms, normal or minimally elevated pancreatic enzymes during painful episodes and no known risk factors, a normal CT scan result is sufficient to exclude the diagnosis. However, if findings on CT scan are normal or equivocal, patients with a higher pretest probability of disease based on symptoms suggesting pancreatic pain or those with other risk factors, such as exposure to alcohol, smoking, or both; family history; presence of diabetes; or clinical or laboratory evidence of exocrine insufficiency, magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) should be considered for further evaluation. Current MRI-MRCP technology can provide high-quality images of both the pancreatic parenchyma and ductal system. Parenchymal changes

Figure 2. Diagnostic Imaging Modalities Used to Identify Morphologic Features of Chronic Pancreatitis



A, Abdominal computed tomographic image of a dilated pancreatic duct (blue arrowhead) and multiple calcified stones (yellow arrowheads) in the body and tail of the pancreas. B, Magnetic resonance cholangiopancreatographic image showing a large stone in the head of the pancreas (yellow arrowhead)

causing obstruction and dilation of the pancreatic duct (blue arrowhead). C, Endoscopic ultrasound image of the head of the pancreas showing a large calcification (yellow arrowhead) with posterior shadowing.

suggesting CP include reduced T1 signal intensity. Ductal changes include main pancreatic duct dilation or irregularity, dilation of the side branches, and the presence of at least 1 stricture. Intravenous secretin administration during MRCP stimulates pancreatic fluid secretion and can improve visualization of the ductal side branches, as shown in a study involving 84 patients with clinically suspected pancreatic disease but whose abdominal ultrasound and CT scan results showed that their ducts appeared to be normal. After administering the secretin, the number of visible ductal side branches increased from 3 (4%) to 53 (63%).⁷⁵ Secretin administration can also help evaluate duodenal filling, which is a dynamic marker of pancreatic exocrine function. In a select subset of patients with a high index of suspicion for CP, an endoscopic ultrasound can be considered if findings on MRI-MRCP are normal or equivocal. Endoscopic ultrasound evaluates for 4 parenchymal and 5 ductal criteria that are used for diagnosis (Table 3). However, the total number of endoscopic ultrasound criteria required for the diagnosis of CP is not well-established due to high interobserver variability.⁷⁷ High false-positive rates from endoscopic ultrasound are found when patients have abdominal pain from dyspepsia,⁷⁸⁻⁸⁰ are older,^{81,82} have a history of smoking or alcohol abuse,^{83,84} are obese,⁸⁵ or have diabetes.⁸⁶ The specificity of endoscopic ultrasound increases if there is a history of acute pancreatitis.^{87,88} Although some clinicians directly assess pancreatic function by aspirating duodenal fluid after injection of secretin, the utility of these tests remains unclear outside of research settings.

Performance characteristics, advantages and disadvantages of the 3 most commonly used imaging modalities to establish the diagnosis of CP are shown in Table 3 with characteristic CP findings of each shown in Figure 2. The sensitivity of each test ranges from 75% to 81%. Sensitivity is modest because the criterion standard used to define CP varies. Although each test performs well in the presence of advanced disease, they are more limited for diagnosing earlier stages of disease. A conceptual understanding of the natural history of disease is also important. Evolution of morphological and functional changes of CP may require years to manifest. For example, manifestation of these changes in patients with idiopathic CP at an early age (ie, <35 years) may be delayed by up to 10 or more


years after the onset of symptoms compared with patients with pancreatitis from excessive alcohol in whom morphological and functional changes of CP may be present either at diagnosis or may develop within a much shorter period after symptom onset. In natural history studies, 1 in 5 patients with acute pancreatitis and 1 in 3 with recurrent acute pancreatitis will progress to CP.⁸⁹ Therefore, if clinical suspicion of CP is high, patients will need follow-up and repeat imaging because it is likely that morphological and functional changes will evolve with time.

Once the diagnosis of CP is confirmed, its etiology should be established. A thorough clinical history to determine the dose and duration of alcohol and tobacco use as well as personal and family history of pancreatitis, hypertriglyceridemia, pancreatic cancer, cystic fibrosis, and celiac disease is important. In young patients without an obvious cause, genetic testing should be considered.^{22,90,91} The delineation of a genetic etiology for CP may reduce repetitive and expensive diagnostic evaluation, assist with determining prognosis (eg, pancreatic cancer risk in *PRSS1* mutation carriers), and guide treatment selection.⁹²

Treatment

Treatment of CP begins with medical management (Figure 2). Among 89 patients with newly diagnosed CP in a population-based study with a mean follow-up of 10 years, 76% of patients experienced pain but only 30% required an invasive treatment such as endoscopy, surgery, or both.⁵⁵ Thus, medical therapies may be adequate for pain management for many patients with only a subset, typically patients with refractory pain, requiring invasive treatment. When applicable, patients should be counseled to abstain from alcohol and smoking because ongoing exposure is associated with pain relapses.⁹³ A study⁹⁴ involving 205 patients with CP followed up for a median of 15.5 years (range, 10-18 years), found that continued alcohol use and smoking were associated with disease progression. Ongoing smoking was associated with reduced efficacy of both endoscopic⁹⁵ and surgical therapeutic intervention.⁹⁶ Because there are no guidelines regarding the choice, use, and dose of analgesics, the 1986 World Health Organization analgesic ladder for cancer pain is commonly used by clinicians for treating

Figure 3. Endoscopic and Surgical Procedures for Treatment



CP pain.⁹⁷ This guideline recommends acetaminophen and nonsteroidal anti-inflammatory drugs (eg, diclofenac, ibuprofen, and naproxen) as first-line, nonopioid analgesics with escalation to weak opioids (eg, tramadol, codeine) and then strong opioids (eg, morphine, oxycodone, fentanyl) depending on the severity of pain. Although, to our knowledge, there are no data regarding opioid abuse and misuse in patients with painful CP, opioid prescribing and monitoring practices should follow the Centers for Disease Control and Prevention guidelines.⁹⁸ Pregabalin has been shown to be effective in a short-term trial, which supports a neuropathic pain mechanism for CP in a subset of patients.⁹⁹ Both coated and uncoated pancreatic enzyme supplements in variable doses are often used by clinicians to treat pain in the absence of exocrine insufficiency,¹⁰⁰ but a meta-analysis of 5 trials has shown equivocal efficacy for pain relief.¹⁰¹ Antioxidant supplementation in combination and in doses of 0.54 g of ascorbic acid, 9000 IU of β -carotene, 270 IU of α -tocopherol, 600 μ g of organic selenium, and 2 g of methionine may be beneficial particularly for those patients with nonalcoholic-derived CP but additional trials are needed.¹⁰²⁻¹⁰⁴ In a double blind randomized trial, 127 consecutive patients with CP (35 alcoholic, 92 with idiopathic CP) were randomized to receive antioxidants or placebo for 6 months.¹⁰¹ The primary outcome measure was pain relief. The reduction in the number of painful days per month was significantly higher in the antioxidant group than in the placebo group (7.4 [SD, 6.8] vs 3.2 [4] $P < .001$; 95% CI,

2.07-6.23). Furthermore, 32% and 13% of patients became pain free in the antioxidant and placebo groups, respectively ($P < .01$).

Endoscopy and surgical resection, drainage procedures, or both can be used to treat pain when medical therapies are unsuccessful. These procedures alleviate pancreatic ductal obstruction from stones, strictures, or both in an effort to reduce intraductal hypertension and thereby pain (Figure 3). The surgical procedures used include partial resection (eg, Whipple, distal pancreatectomy), drainage (eg, Puestow) and combined partial resection and drainage procedures (eg, Frey, Berne, and Beger). Extracorporeal shock wave lithotripsy (ESWL) may be used as an adjunctive therapy to fragment large stones prior to endoscopic removal, but this procedure is not US Food and Drug Administration–approved for pancreatic stones and requires the assistance of a urologist at US centers. Neuroablative techniques such as endoscopic celiac plexus blockade have been evaluated in 3 trials consisting of 151 patients and have reported pain relief rates of 53% to 60% over 4 to 8 weeks of follow-up after the procedure.¹⁰⁵ However, a more recent trial of 40 patients with CP, with stricter inclusion criteria for CP, compared different injected treatments for celiac plexus blockade and reported that only 6 patients (15%) experienced overall pain relief at 1 month, which raises the question of whether this procedure is an appropriate option for patients.^{106,107}

Table 4 shows the characteristics, outcomes, and adverse events of high-quality medical and interventional randomized clinical trials

Table 4. Randomized Controlled Trials Evaluating Pain Relief of Medical and Interventional Therapies for Painful Chronic Pancreatitis

Source	No. of Patients	Comparison	Primary Outcome	Duration of Follow-up	Pain Relief	Adverse Events
Bhardwaj et al, ¹⁰³ 2008	127	Antioxidants (dose: 0.54 g ascorbic acid, 9000 IU β -carotene, 270 IU α -tocopherol, 600 μ g organic selenium, and 2 g methionine per d) vs placebo	Reduction in painful d/mo at 6 mo	6 mo	Reduction in mean (SD) number of painful d/mo 7.4 (6.8) vs 3.2 (4) ($P < .001$) (mainly idiopathic CP)	No significant adverse events noted except headache in 8 and constipation in 4 patients taking antioxidants (n = 71)
Siriwardena et al, ¹⁰² 2012	70	Antioxidants (dose: 2 tablets 3/d, contained 38.5 mg selenium yeast, of which 50 μ g was l-selenomethionine; 113.4 mg/d α -tocopherol acetate; 126.3 mg ascorbic acid; and 480 mg l-methionine) vs placebo	Change in clinic pain score at 6 mo	6 mo	Nonsignificant reduction in pain score by 2.33 vs 1.97; $P = .50$, mainly alcoholic CP taking 85 mg of morphine/d)	No significant adverse events noted except 1 patient had diarrhea and 1 developed hepatic encephalopathy in the antioxidant group
Olesen et al, ⁹⁹ 2011	64	Pregabalin (75 mg 2/d, increased to 300 mg 2/d after 1 wk) vs placebo	Change in pain intensity as measured on a visual analogue scale after 3 wk of treatment	3 wk	36% vs 24% ($P = .02$)	Four of 34 Patients in the pregabalin group had serious adverse events: pneumonia, worsening abdominal pain, eczema, and shoulder injury in 1 patient each; 35% and 24% of patients taking pregabalin reported feeling drunk and light-headedness
Talukdar et al, ¹⁰⁸ 2016	87	Antioxidants + pregabalin vs placebo	Pain relief measured on visual analogue scale and Izbicik pain score	2 mo	48% vs 27% ($P = .04$)	Mild to moderate self-limiting nausea and vomiting in the treatment group
Dumonceau et al, ¹⁰⁹ 2007	55	ESWL vs ERCP + ESWL	Pain relapse	2 y	58% vs 55% ($P = .63$)	3% Complication (1 patient developed pseudocyst) in the ERCP + ESWL group
Dite et al, ¹¹⁰ 2003	72	ERCP (no ESWL) vs surgery	Complete pain relief	5 y	15% vs 34% ($P = .002$)	8% Patients in each group had complications
Cahen et al, ¹¹¹ 2007	39	ERCP + ESWL vs surgery	Complete pain relief	2 y	16% vs 40% ($P = .007$)	11 Patients (58%) had minor complications in the endoscopy group and 7 (35%) had complications in the surgery group
Cahen et al, ¹¹² 2011	31	ERCP + ESWL vs Surgery	Complete pain relief	6.5 y (follow-up of RCT from 2007)	25% vs 53% ($P = .04$)	47% Of patients in the endoscopy group required surgery

Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; ESWL, extracorporeal shock wave lithotripsy; RCT, randomized clinical trial.

for painful CP. Limitations of these studies include relatively short duration of follow-up, small numbers of patients, lack of a validated pain assessment tool for CP, lack of a sham-placebo group and heterogeneity with regards to the use of ESWL. In 2 randomized trials involving patients with CP and ductal obstruction, surgery was associated with greater pain relief than was endoscopy. The first trial¹¹⁰ randomized 72 patients and found complete pain relief rates of 15% with ERCP (without ESWL) compared with 34% with surgery over 5 years of follow-up. The second trial¹¹¹ randomized 39 patients and found complete pain relief rates of 16% with ERCP (with ESWL as needed) compared with 40% with surgery over a 2-year follow-up with continued complete pain relief in 25% vs 53%, respectively, over 6.5 years of follow-up.¹¹² A Cochrane review of these 2 trials including 111 patients with follow-up data showed that surgery was associated with a higher proportion of patients with pain relief at 2 to 5 years (risk ratio [RR], 1.62; 95% CI, 1.22-2.15) and more than 5 years (RR, 1.56; 95% CI, 1.18-2.05) compared with endoscopy.¹¹³

A recent clinical trial, comparing the cost effectiveness of endoscopy and surgery, equally randomized 38 CP patients and found a higher mean number of ERCPs performed in the endoscopy group (6.3 vs 0.4) than in the surgery group.¹¹⁴ Despite the efficacy of sur-

gery and frequent requirement for repeated procedures among people who undergo endoscopy, many patients initially prefer endoscopic therapy because it is less invasive. Surgery may be an appropriate first-line treatment for patients with CP who have large and numerous pancreatic stones or complex strictures, an inflammatory head mass, or disease limited to the pancreatic tail. Endoscopy may be preferred when there are 3 or fewer small (<1 cm) stones located in the head and body of the pancreas.¹¹⁵ Pain relief was reported in nearly 70% of patients initially treated with multiple medical therapies followed by endoscopy, surgery, or both as needed over 15 years of follow-up.⁷⁰ Total pancreatectomy with or without islet autotransplantation is increasingly a therapeutic option in a subset of patients with genetic or idiopathic CP whose pain does not respond to medical or endoscopic therapy with pain relief rates as high as 90% in a single-center series of 80 patients.¹¹⁶ Longitudinal data from an ongoing prospective multicenter registry study will determine the optimal role of this strategy in the management of CP.¹¹⁷

Initial evaluation and monitoring of patients with CP should include an assessment of functional deficiencies. Symptoms of steatorrhea (foul smelling, oily stool), diarrhea and weight loss suggest exocrine sufficiency. Steatorrhea or fat malabsorption is defined

as a coefficient of fat absorption (CFA) of less than 93% (or >7 g of fat per 24 hours from a 72-hour fecal fat collection in a patient who is consuming 100 g of dietary fat each day during stool collection). The 72-hour fecal fat test is the criterion standard for steatorrhea but lacks specificity for pancreatic exocrine insufficiency because it cannot differentiate between different causes of fat malabsorption. Furthermore, the test is difficult to perform properly, contributing to a decline in its use. Although there are several other indirect (eg, fecal elastase or FE-1, serum trypsin) and direct tests (endoscopic secretin) used to diagnose exocrine insufficiency,¹¹⁸ the accuracy of these tests is highest in the presence of severe exocrine insufficiency when defined as steatorrhea. For example, a study involving 54 patients with CP who underwent both CFA and FE-1 testing, an FE-1 cutoff of 84 µg/g (FE-1 < 100 µg/g is considered severe exocrine insufficiency) was found to have a sensitivity of 87.5% and specificity of 81.6% but a FE-1 cutoff of 200 µg/g was found to have a sensitivity of 93.8% but a low specificity of 63.2%.¹¹⁸ No established criterion standard exists for mild to moderate exocrine insufficiency. Thus, dietary counseling¹¹⁹ and pancreatic enzymes should be administered in patients with symptoms consistent with exocrine insufficiency even if diagnostic testing is equivocal. Pancreatic enzymes at doses of 1000 USP units of lipase per kilogram per meal should be administered during meals because they are effective for treating malabsorption as well as improving nutritional parameters and quality of life.¹²⁰ Vitamin D levels and bone density studies should be considered to assess for osteopenia and osteoporosis given the risk of low trauma fracture.¹²¹ Biannual fasting glucose and glycated hemoglobin should be obtained to assess for diabetes.¹²² During follow-up, if symptoms change or new symptoms develop, imaging with CT or MRI should be obtained to assess for and treat any CP complications.

Prognosis

Median survival in patients with CP has been reported to be 15 to 20 years after diagnosis.¹²³ In another study involving 411 patients with CP, the probability of survival up to 35 years after the onset of symptoms was 83%.¹³ Survival is affected by complications of CP, adverse effects of alcoholism, smoking, and diabetes. One study showed a standardized incidence ratio (SIR) of 26.3 (95% CI, 19.9-34.2) for pancreatic cancer in patients with CP. The cumulative risk of pancreatic cancer was 1.8% at 10 years and 4% at 20 years of follow-up.¹²⁴ The risk may be higher for those with genetically determined CP.¹²⁵ In patients with hereditary pancreatitis, the risk of pancreatic cancer was significantly greater than age- and sex-matched Surveillance, Epidemiology, and End Results data (SIR, 59; 95% CI, 19-138). The cumulative risk was 7.2% (95% CI, 0%-15.4%) at 70 years and the median overall survival was 79.3 years (interquartile range [IQR], 72.2-85.2 years).¹²⁶ Currently, guidelines do not recommend routine screening of patients with CP for pancreatic cancer except in those with *PRSS1* mutation; however, there is no consensus yet on the frequency and mode of screening for these individuals. Computed tomographic scanning should be considered for patients with weight loss associated with CP, jaundice, and new-onset pain after a long pain-free interval to evaluate for pancreatic cancer.

Conclusions

Chronic pancreatitis often results in chronic abdominal pain and is most commonly caused by excessive alcohol use, smoking, or genetic mutations. Treatment consists primarily of alcohol and smoking cessation, pain control, replacement of pancreatic insufficiencies, and mechanical drainage of obstructed pancreatic ducts in some patients.

ARTICLE INFORMATION

Accepted for Publication: November 19, 2019.

Author Contributions: Dr Singh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Singh, Garg.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: Singh.

Supervision: Singh.

Conflict of Interest Disclosures: Dr Singh reports receiving personal fees from Abbvie, Theraly Inc, Cook Medical, Orgenesis, and Ariel Precision Medicine. Dr Yadav is supported by the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award U01 DK 108306. Dr Garg is supported by a grant from the Center for Advanced Research and Excellence in Pancreatic Diseases by the Indian Council of Medical Research.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional Contributions: We thank Kajal Jain, PhD, All India Institute of Medical Sciences, New Delhi, and Mahya Faghih, MD, Division of Gastroenterology, Johns Hopkins University School of Medicine, for helping to put together this review.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Edward Livingston, MD, at edward.livingston@jamanetwork.org or Mary McGrae McDermott, MD, at mdm608@northwestern.edu.

REFERENCES

- Yadav D, Timmons L, Benson JT, Dierkhising RA, Chari ST. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. *Am J Gastroenterol*. 2011;106(12):2192-2199. doi:10.1038/ajg.2011.328
- Machicado JD, Dudekula A, Tang G, et al. Period prevalence of chronic pancreatitis diagnosis from 2001-2013 in the commercially insured population of the United States. *Pancreatol*. 2019;19(6):813-818. doi:10.1016/j.pan.2019.07.003
- Yadav D, Muddana V, O'Connell M. Hospitalizations for chronic pancreatitis in Allegheny County, Pennsylvania, USA. *Pancreatol*. 2011;11(6):546-552. doi:10.1159/000331498
- Hirota M, Shimosegawa T, Masamune A, et al; Research Committee of Intractable Pancreatic Diseases. The sixth nationwide epidemiological survey of chronic pancreatitis in Japan. *Pancreatol*. 2012;12(2):79-84. doi:10.1016/j.pan.2012.02.005
- Garg PK. Chronic pancreatitis in India and Asia. *Curr Gastroenterol Rep*. 2012;14(2):118-124. doi:10.1007/s11894-012-0241-0
- Whitcomb DC, Frulloni L, Garg P, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. *Pancreatol*. 2016;16(2):218-224. doi:10.1016/j.pan.2016.02.001
- Yadav D, Hawes RH, Brand RE, et al; North American Pancreatic Study Group. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. *Arch Intern Med*. 2009;169(11):1035-1045. doi:10.1001/archinternmed.2009.125
- Kristiansen L, Grønbaek M, Becker U, Tolstrup JS. Risk of pancreatitis according to alcohol drinking habits: a population-based cohort study. *Am J Epidemiol*. 2008;168(8):932-937. doi:10.1093/aje/kwn222
- Tolstrup JS, Kristiansen L, Becker U, Grønbaek M. Smoking and risk of acute and chronic pancreatitis among women and men: a population-based cohort study. *Arch Intern Med*. 2009;169(6):603-609. doi:10.1001/archinternmed.2008.601
- Rosendahl J, Landt O, Bernadova J, et al. *CFTR*, *SPINK1*, *CTRC* and *PRSS1* variants in chronic pancreatitis: is the role of mutated *CFTR*

- overestimated? *Gut*. 2013;62(4):582-592. doi:10.1136/gutjnl-2011-300645
11. Zou WB, Tang XY, Zhou DZ, et al. *SPINK1*, *PRSS1*, *CTRC*, and *CFTR* genotypes influence disease onset and clinical outcomes in chronic pancreatitis. *Clin Transl Gastroenterol*. 2018;9(11):204. doi:10.1038/s41424-018-0069-5
 12. Pfützer RH, Barmada MM, Brunskill AP, et al. *SPINK1/PS1* polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. *Gastroenterology*. 2000;119(3):615-623. doi:10.1053/gast.2000.18017
 13. Midha S, Khajuria R, Shastri S, Kabra M, Garg PK. Idiopathic chronic pancreatitis in India: phenotypic characterisation and strong genetic susceptibility due to *SPINK1* and *CFTR* gene mutations. *Gut*. 2010;59(6):800-807. doi:10.1136/gut.2009.191239
 14. Paliwal S, Bhaskar S, Mani KR, et al. Comprehensive screening of chymotrypsin C (*CTRC*) gene in tropical calcific pancreatitis identifies novel variants. *Gut*. 2013;62(11):1602-1606. doi:10.1136/gutjnl-2012-302448
 15. Witt H, Beer S, Rosendahl J, et al. Variants in *CPA1* are strongly associated with early onset chronic pancreatitis. *Nat Genet*. 2013;45(10):1216-1220. doi:10.1038/ng.2730
 16. Whitcomb DC, LaRusch J, Krasinskas AM, et al. Common genetic variants in the *CLDN2* and *PRSS1-PRSS2* loci alter risk for alcohol-related and sporadic pancreatitis. *Nat Genet*. 2012;44(12):1349-1354. doi:10.1038/ng.2466
 17. Giri AK, Midha S, Banerjee P, et al; INDIPAN and INDICO Consortium. Common variants in *CLDN2* and *MORC4* genes confer disease susceptibility in patients with chronic pancreatitis. *PLoS One*. 2016;11(1):e0147345. doi:10.1371/journal.pone.0147345
 18. Fjeld K, Weiss FU, Lasher D, et al. A recombined allele of the lipase gene *CEL* and its pseudogene *CELP* confers susceptibility to chronic pancreatitis. *Nat Genet*. 2015;47(5):518-522. doi:10.1038/ng.3249
 19. Ludvigsson JF, Montgomery SM, Ekblom A. Risk of pancreatitis in 14,000 individuals with celiac disease. *Clin Gastroenterol Hepatol*. 2007;5(11):1347-1353. doi:10.1016/j.cgh.2007.06.002
 20. Wilcox CM, Sandhu BS, Singh V, et al. Racial differences in the clinical profile, causes, and outcome of chronic pancreatitis. *Am J Gastroenterol*. 2016;111(10):1488-1496. doi:10.1038/ajg.2016.316
 21. Hao L, Wang LS, Liu Y, et al. The different course of alcoholic and idiopathic chronic pancreatitis: A long-term study of 2,037 patients. *PLoS One*. 2018;13(6):e0198365. doi:10.1371/journal.pone.0198365
 22. Jalaly NY, Moran RA, Fargahi F, et al. An evaluation of factors associated with pathogenic *PRSS1*, *SPINK1*, *CTFR*, and/or *CTRC* genetic variants in patients with idiopathic pancreatitis. *Am J Gastroenterol*. 2017;112(8):1320-1329. doi:10.1038/ajg.2017.106
 23. Aslam M, Talukdar R, Jagtap N, et al. Clinical profile and outcome of parathyroid adenoma-associated pancreatitis. *Saudi J Med Sci*. 2018;6(2):95-99. doi:10.4103/sjms.sjms_80_17
 24. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMaggio EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. *Gastroenterology*. 1994;107(5):1481-1487. doi:10.1016/0016-5085(94)90553-3
 25. Apte MV, Pirola RC, Wilson JS. Mechanisms of alcoholic pancreatitis. *J Gastroenterol Hepatol*. 2010;25(12):1816-1826. doi:10.1111/j.1440-1746.2010.06445.x
 26. Lee AT, Xu Z, Pothula SP, et al. Alcohol and cigarette smoke components activate human pancreatic stellate cells: implications for the progression of chronic pancreatitis. *Alcohol Clin Exp Res*. 2015;39(11):2123-2133. doi:10.1111/acer.12882
 27. Maléth J, Balázs A, Pallagi P, et al. Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology*. 2015;148(2):427-39.e16. doi:10.1053/j.gastro.2014.11.002
 28. Alahmari AA, Sreekumar B, Patel V, et al. Cigarette toxin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces experimental pancreatitis through $\alpha 7$ nicotinic acetylcholine receptors (nAChRs) in mice. *PLoS One*. 2018;13(6):e0197362. doi:10.1371/journal.pone.0197362
 29. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nat Genet*. 1996;14(2):141-145. doi:10.1038/ng1096-141
 30. Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (*CTRC*) variants that diminish activity or secretion are associated with chronic pancreatitis. *Nat Genet*. 2008;40(1):78-82. doi:10.1038/ng.2007.44
 31. Sahin-Tóth M. Genetic risk in chronic pancreatitis: the misfolding-dependent pathway. *Curr Opin Gastroenterol*. 2017;33(5):390-395. doi:10.1097/MOG.0000000000000380
 32. Gukovskaya AS, Gukovsky I, Algül H, Habtezion A. Autophagy, inflammation, and immune dysfunction in the pathogenesis of pancreatitis. *Gastroenterology*. 2017;153(5):1212-1226. doi:10.1053/j.gastro.2017.08.071
 33. Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-Tóth M. Genetics, cell biology, and pathophysiology of pancreatitis. *Gastroenterology*. 2019;156(7):1951-1968.e1. doi:10.1053/j.gastro.2018.11.081
 34. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med*. 1998;339(10):645-652. doi:10.1056/NEJM199809033391001
 35. Aghdassi AA, Weiss FU, Mayerle J, Lerch MM, Simon P. Genetic susceptibility factors for alcohol-induced chronic pancreatitis. *Pancreatology*. 2015;15(4)(suppl):S23-S31. doi:10.1016/j.pan.2015.05.476
 36. Apte MV, Pirola RC, Wilson JS. Individual susceptibility to alcoholic pancreatitis. *J Gastroenterol Hepatol*. 2008;23(suppl 1):S63-S68. doi:10.1111/j.1440-1746.2007.05287.x
 37. Gu H, Werner J, Bergmann F, Whitcomb DC, Büchler MW, Fortunato F. Necro-inflammatory response of pancreatic acinar cells in the pathogenesis of acute alcoholic pancreatitis. *Cell Death Dis*. 2013;4:e816. doi:10.1038/cddis.2013.354
 38. Watanabe T, Kudo M, Strober W. Immunopathogenesis of pancreatitis. *Mucosal Immunol*. 2017;10(2):283-298. doi:10.1038/mi.2016.101
 39. Xue J, Sharma V, Hsieh MH, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. *Nat Commun*. 2015;6:7158. doi:10.1038/ncomms8158
 40. Tandon RK, Garg PK. Oxidative stress in chronic pancreatitis: pathophysiological relevance and management. *Antioxid Redox Signal*. 2011;15(10):2757-2766. doi:10.1089/ars.2011.4115
 41. Omary MB, Lugea A, Lowe AW, Pandolfi SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. *J Clin Invest*. 2007;117(1):50-59. doi:10.1172/JCI30082
 42. Apte M, Pirola R, Wilson J. The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells. *Antioxid Redox Signal*. 2011;15(10):2711-2722. doi:10.1089/ars.2011.4079
 43. Shrikhande SV, Martignoni ME, Shrikhande M, et al. Comparison of histological features and inflammatory cell reaction in alcoholic, idiopathic and tropical chronic pancreatitis. *Br J Surg*. 2003;90(12):1565-1572. doi:10.1002/bjs.4353
 44. Stevens T, Conwell DL, Zuccaro G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. *Am J Gastroenterol*. 2004;99(11):2256-2270. doi:10.1111/j.1572-0241.2004.40694.x
 45. Ammann RW, Muellhaupt B. Progression of alcoholic acute to chronic pancreatitis. *Gut*. 1994;35(4):552-556. doi:10.1136/gut.35.4.552
 46. Hori Y, Vege SS, Chari ST, et al. Classic chronic pancreatitis is associated with prior acute pancreatitis in only 50% of patients in a large single-institution study. *Pancreatology*. 2019;19(2):224-229. doi:10.1016/j.pan.2019.02.004
 47. Olesen SS, Drewes AM, Novovic S, Nøjgaard C. The sentinel acute pancreatitis event hypothesis revisited. *Pancreatology*. 2019;19(4):614-615. doi:10.1016/j.pan.2019.03.007
 48. Sarles H, Bernard JP, Gullo L. Pathogenesis of chronic pancreatitis. *Gut*. 1990;31(6):629-632. doi:10.1136/gut.31.6.629
 49. Hegyi P, Wilschanski M, Muallem S, et al. *CFTR*: a new horizon in the pathomechanism and treatment of pancreatitis. *Rev Physiol Biochem Pharmacol*. 2016;170:37-66. doi:10.1007/112_2015_5002
 50. Wilcox CM, Seay T, Kim H, Varadarajulu S. Prospective endoscopic ultrasound-based approach to the evaluation of idiopathic pancreatitis: causes, response to therapy, and long-term outcome. *Am J Gastroenterol*. 2016;111(9):1339-1348. doi:10.1038/ajg.2016.240
 51. Coté GA, Imperiale TF, Schmidt SE, et al. Similar efficacies of biliary, with or without pancreatic, sphincterotomy in treatment of idiopathic recurrent acute pancreatitis. *Gastroenterology*. 2012;143(6):1502-1509.e1. doi:10.1053/j.gastro.2012.09.006
 52. Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. *JAMA*. 2014;311(20):2101-2109. doi:10.1001/jama.2014.5220
 53. Olesen SS, Juel J, Nielsen AK, Frøkjær JB, Wilder-Smith OH, Drewes AM. Pain severity reduces life quality in chronic pancreatitis: Implications for design of future outcome trials. *Pancreatology*. 2014;14(6):497-502. doi:10.1016/j.pan.2014.09.009

54. Schwarzenberg SJ, Uc A, Zimmerman B, et al. Chronic pancreatitis: pediatric and adult cohorts show similarities in disease progress despite different risk factors. *J Pediatr Gastroenterol Nutr.* 2019;68(4):566-573. doi:10.1097/MPG.0000000000002279
55. Machicado JD, Chari ST, Timmons L, Tang G, Yadav D. A population-based evaluation of the natural history of chronic pancreatitis. *Pancreatol.* 2018;18(1):39-45. doi:10.1016/j.pan.2017.11.012
56. Garg PK, Tandon RK. Survey on chronic pancreatitis in the Asia-Pacific region. *J Gastroenterol Hepatol.* 2004;19(9):998-1004. doi:10.1111/j.1440-1746.2004.03426.x
57. Li BR, Pan J, Du TT, et al. Risk factors for steatorrhea in chronic pancreatitis: a cohort of 2,153 patients. *Sci Rep.* 2016;6:21381. doi:10.1038/srep21381
58. Wilcox CM, Yadav D, Ye T, et al. Chronic pancreatitis pain pattern and severity are independent of abdominal imaging findings. *Clin Gastroenterol Hepatol.* 2015;13(3):552-560. doi:10.1016/j.cgh.2014.10.015
59. Greer JB, Greer P, Sandhu BS, et al. Nutrition and inflammatory biomarkers in chronic pancreatitis patients. *Nutr Clin Pract.* 2019;34(3):387-399. doi:10.1002/ncp.10186
60. Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. *Anticancer Res.* 2012;32(5):1991-1998.
61. Duggan SN, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2014;12(2):219-228. doi:10.1016/j.cgh.2013.06.016
62. Munigala S, Agarwal B, Gelrud A, Conwell DL. Chronic pancreatitis and fracture: a retrospective, population-based Veterans Administration study. *Pancreas.* 2016;45(3):355-361. doi:10.1097/MPA.0000000000000381
63. Tignor AS, Wu BU, Whitlock TL, et al. High prevalence of low-trauma fracture in chronic pancreatitis. *Am J Gastroenterol.* 2010;105(12):2680-2686. doi:10.1038/ajg.2010.325
64. Bang UC, Benfield T, Bendtsen F, Hyldstrup L, Beck Jensen JE. The risk of fractures among patients with cirrhosis or chronic pancreatitis. *Clin Gastroenterol Hepatol.* 2014;12(2):320-326. doi:10.1016/j.cgh.2013.04.031
65. Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. *Gastroenterology.* 2000;119(5):1324-1332. doi:10.1053/gast.2000.19286
66. Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. *Gastroenterology.* 2009;136(1):177-186.e1. doi:10.1053/j.gastro.2008.09.029
67. Olesen SS, Krauss T, Demir IE, et al. Towards a neurobiological understanding of pain in chronic pancreatitis: mechanisms and implications for treatment. *Pain Rep.* 2017;2(6):e625. doi:10.1097/PR9.0000000000000625
68. Muthulingam J, Olesen SS, Hansen TM, et al. Progression of structural brain changes in patients with chronic pancreatitis and its association to chronic pain: a 7-year longitudinal follow-up study. *Pancreas.* 2018;47(10):1267-1276. doi:10.1097/MPA.0000000000001151
69. Bouwense SA, Ahmed Ali U, ten Broek RP, et al. Altered central pain processing after pancreatic surgery for chronic pancreatitis. *Br J Surg.* 2013;100(13):1797-1804. doi:10.1002/bjs.9322
70. Shalimar MS, Midha S, Hasan A, Dhingra R, Garg PK. Long-term pain relief with optimized medical treatment including antioxidants and step-up interventional therapy in patients with chronic pancreatitis. *J Gastroenterol Hepatol.* 2017;32(1):270-277. doi:10.1111/jgh.13410
71. Ammann RW, Muellhaupt B. The natural history of pain in alcoholic chronic pancreatitis. *Gastroenterology.* 1999;116(5):1132-1140. doi:10.1016/S0016-5085(99)70016-8
72. Frøkjær JB, Olesen SS, Drewes AM. Fibrosis, atrophy, and ductal pathology in chronic pancreatitis are associated with pancreatic function but independent of symptoms. *Pancreas.* 2013;42(7):1182-1187. doi:10.1097/MPA.0b013e31829628f4
73. Bornman PC, Marks IN, Girdwood AH, et al. Is pancreatic duct obstruction or stricture a major cause of pain in calcific pancreatitis? *Br J Surg.* 1980;67(6):425-428. doi:10.1002/bjs.1800670614
74. Zhu X, Liu D, Wei Q, et al. New-onset diabetes mellitus after chronic pancreatitis diagnosis: a systematic review and meta-analysis [published online August 2019]. *Pancreas.* 2019;48(7):868-875. doi:10.1097/MPA.0000000000001359
75. Manfredi R, Costamagna G, Brizi MG, et al. Severe chronic pancreatitis versus suspected pancreatic disease: dynamic MR cholangiopancreatography after secretin stimulation. *Radiology.* 2000;214(3):849-855. doi:10.1148/radiology.214.3.r00mr24849
76. Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boermeester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. *Eur Radiol.* 2017;27(9):3820-3844. doi:10.1007/s00330-016-4720-9
77. Gardner TB, Gordon SR. Interobserver agreement for pancreatic endoscopic ultrasonography determined by same day back-to-back examinations. *J Clin Gastroenterol.* 2011;45(6):542-545. doi:10.1097/MCG.0b013e318f42d69
78. Sahai AV, Mishra G, Penman ID, et al. EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia. *Gastrointest Endosc.* 2000;52(2):153-159. doi:10.1067/mge.2000.107910
79. Hashimoto S, Futagami S, Yamawaki H, et al. Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography. *J Clin Biochem Nutr.* 2017;61(2):140-145. doi:10.3164/jcbn.17-41
80. Lariño-Noia J, de la Iglesia D, Iglesias-García J, et al. Morphological and functional changes of chronic pancreatitis in patients with dyspepsia: A prospective, observational, cross-sectional study. *Pancreatol.* 2018;18(3):280-285. doi:10.1016/j.pan.2018.02.003
81. Bhutani MS, Arantes VN, Verma D, et al. Histopathologic correlation of endoscopic ultrasound findings of chronic pancreatitis in human autopsies. *Pancreas.* 2009;38(7):820-824. doi:10.1097/MPA.0b013e3181b2bcla
82. Rajan E, Clain JE, Levy MJ, et al. Age-related changes in the pancreas identified by EUS: a prospective evaluation. *Gastrointest Endosc.* 2005;61(3):401-406. doi:10.1016/S0016-5107(04)02758-0
83. Yusoff IF, Sahai AV. A prospective, quantitative assessment of the effect of ethanol and other variables on the endosonographic appearance of the pancreas. *Clin Gastroenterol Hepatol.* 2004;2(5):405-409. doi:10.1016/S1542-3565(04)00126-0
84. Petrone MC, Arcidiacono PG, Perri F, Carrara S, Boemo C, Testoni PA. Chronic pancreatitis-like changes detected by endoscopic ultrasound in subjects without signs of pancreatic disease: do these indicate age-related changes, effects of xenobiotics, or early chronic pancreatitis? *Pancreatol.* 2010;10(5):597-602. doi:10.1159/000314599
85. Al-Haddad M, Khashab M, Zyromski N, et al. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. *Pancreas.* 2009;38(6):672-675. doi:10.1097/MPA.0b013e3181a9d5af
86. Bolado F, Prieto C, Vila JJ, Fernandez-Urien I, Forga L, Zozaya JM. Chronic pancreatitis-like changes detected by endoscopic ultrasound in type 1 diabetics are not associated with gastrointestinal symptoms or nutritional deficiencies. *Pancreas.* 2017;46(1):102-105. doi:10.1097/MPA.0000000000000671
87. Albashir S, Bronner MP, Parsi MA, Walsh RM, Stevens T. Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. *Am J Gastroenterol.* 2010;105(11):2498-2503. doi:10.1038/ajg.2010.274
88. Trikudanathan G, Vega-Peralta J, Malli A, et al. Diagnostic performance of endoscopic ultrasound (EUS) for non-calcific chronic pancreatitis (NCCP) based on histopathology. *Am J Gastroenterol.* 2016;111(4):568-574. doi:10.1038/ajg.2016.48
89. Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. *Gastroenterology.* 2015;149(6):1490-1500.e1. doi:10.1053/j.gastro.2015.07.066
90. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. *N Engl J Med.* 1998;339(10):653-658. doi:10.1056/NEJM199809033391002
91. Audrézet MP, Chen JM, Le Maréchal C, et al. Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. *Eur J Hum Genet.* 2002;10(2):100-106. doi:10.1038/sj.ejhg.5200786
92. Sun C, Liu MY, Liu XG, et al. Serine protease inhibitor Kazal type 1 (SPINK1) c.194+2T > C mutation may predict long-term outcome of endoscopic treatments in idiopathic chronic pancreatitis. *Medicine (Baltimore).* 2015;94(47):e2046. doi:10.1097/MD.0000000000002046
93. Olesen SS, Kuhlmann L, Novovic S, et al. Association of multiple patient and disease characteristics with the presence and type of pain

- in chronic pancreatitis [published online July 17, 2019]. doi:10.111/jgh.14783
94. Talamini G, Bassi C, Falconi M, et al. Pain relapses in the first 10 years of chronic pancreatitis. *Am J Surg*. 1996;171(6):565-569. doi:10.1016/S0002-9610(97)89604-3
 95. Delhaye M, Arvanitakis M, Verset G, Cremer M, Devière J. Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2004;2(12):1096-1106. doi:10.1016/S1542-3565(04)00544-0
 96. Bordačahar B, Couvelard A, Vullierme MP, et al. Predicting the efficacy of surgery for pain relief in patients with alcoholic chronic pancreatitis. *Surgery*. 2018;164(5):1064-1070. doi:10.1016/j.surg.2018.05.025
 97. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. *JAMA*. 1995;274(23):1870-1873. doi:10.1001/jama.1995.03530230056031
 98. Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464
 99. Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. *Gastroenterology*. 2011;141(2):536-543. doi:10.1053/j.gastro.2011.04.003
 100. Burton F, Alkaade S, Collins D, et al; North American Pancreatic Study Group. Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. *Aliment Pharmacol Ther*. 2011;33(1):149-159. doi:10.1111/j.1365-2036.2010.04491.x
 101. Yaghoobi M, McNabb-Baltar J, Bijarchi R, Cotton PB. Pancreatic enzyme supplements are not effective for relieving abdominal pain in patients with chronic pancreatitis: meta-analysis and systematic review of randomized controlled trials. *Can J Gastroenterol Hepatol*. 2016;2016:8541839. doi:10.1155/2016/8541839
 102. Siriwardena AK, Mason JM, Sheen AJ, Makin AJ, Shah NS. Antioxidant therapy does not reduce pain in patients with chronic pancreatitis: the ANTICIPATE study. *Gastroenterology*. 2012;143(3):655-663.e1. doi:10.1053/j.gastro.2012.05.046
 103. Bhardwaj P, Garg PK, Maulik SK, Saraya A, Tandon RK, Acharya SK. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. *Gastroenterology*. 2009;136(1):149-159.e2. doi:10.1053/j.gastro.2008.09.028
 104. Rustagi T, Njei B. Antioxidant therapy for pain reduction in patients with chronic pancreatitis: a systematic review and meta-analysis. *Pancreas*. 2015;44(5):812-818. doi:10.1097/MPA.0000000000000327
 105. Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. *J Clin Gastroenterol*. 2010;44(2):127-134. doi:10.1097/MCG.0b013e3181bb854d
 106. Stevens T, Costanzo A, Lopez R, Kapural L, Parsi MA, Vargo JJ. Adding triamcinolone to endoscopic ultrasound-guided celiac plexus blockade does not reduce pain in patients with chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2012;10(2):186-191, 191.e1. doi:10.1016/j.cgh.2011.09.006
 107. Smart RG. Health warning labels for alcoholic beverages in Canada. *Can J Public Health*. 1990;81(4):280-284.
 108. Talukdar R, Lakhtakia S, Nageshwar Reddy D, et al. Ameliorating effect of antioxidants and pregabalin combination in pain recurrence after ductal clearance in chronic pancreatitis: Results of a randomized, double blind, placebo-controlled trial. *J Gastroenterol Hepatol*. 2016;31(9):1654-1662. doi:10.1111/jgh.13332
 109. Dumonceau JM, Costamagna G, Tringali A, et al. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial. *Gut*. 2007;56(4):545-552. doi:10.1136/gut.2006.096883
 110. Díte P, Ruzicka M, Zboril V, Novotný I. A prospective, randomized trial comparing endoscopic and surgical therapy for chronic pancreatitis. *Endoscopy*. 2003;35(7):553-558. doi:10.1055/s-2003-40237
 111. Cahen DL, Gouma DJ, Nio Y, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. *N Engl J Med*. 2007;356(7):676-684. doi:10.1056/NEJMoa060610
 112. Cahen DL, Gouma DJ, Laramée P, et al. Long-term outcomes of endoscopic vs surgical drainage of the pancreatic duct in patients with chronic pancreatitis. *Gastroenterology*. 2011;141(5):1690-1695. doi:10.1053/j.gastro.2011.07.049
 113. Ahmed Ali U, Pahlplatz JM, Nealon WH, van Goor H, Gooszen HG, Boermeester MA. Endoscopic or surgical intervention for painful obstructive chronic pancreatitis. *Cochrane Database Syst Rev*. 2015;(3):CD007884. doi:10.1002/14651858.CD007884.pub3
 114. Laramée P, Wonderling D, Cahen DL, et al. Trial-based cost-effectiveness analysis comparing surgical and endoscopic drainage in patients with obstructive chronic pancreatitis. *BMJ Open*. 2013;3(9):e003676. doi:10.1136/bmjopen-2013-003676
 115. Dumonceau JM, Delhaye M, Tringali A, et al. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline—updated August 2018. *Endoscopy*. 2019;51(2):179-193. doi:10.1055/a-0822-0832
 116. Chinnakotla S, Radosevich DM, Dunn TB, et al. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg*. 2014;218(4):530-543. doi:10.1016/j.jamcollsurg.2013.12.037
 117. Bellin MD, Abu-El-Hajja M, Morgan K, et al; POST study consortium. A multicenter study of total pancreatectomy with islet autotransplantation (TPIAT): POST (Prospective Observational Study of TPIAT). *Pancreatology*. 2018;18(3):286-290. doi:10.1016/j.pan.2018.02.001
 118. Domínguez-Muñoz JED, D Hardt P, Lerch MM, Löhr MJ. Potential for screening for pancreatic exocrine insufficiency using the fecal elastase-1 test. *Dig Dis Sci*. 2017;62(5):1119-1130. doi:10.1007/s10620-017-4524-z
 119. Singh S, Midha S, Singh N, Joshi YK, Garg PK. Dietary counseling versus dietary supplements for malnutrition in chronic pancreatitis: a randomized controlled trial. *Clin Gastroenterol Hepatol*. 2008;6(3):353-359. doi:10.1016/j.cgh.2007.12.040
 120. de la Iglesia-García D, Huang W, Szatmary P, et al; NIHR Pancreas Biomedical Research Unit Patient Advisory Group. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. *Gut*. 2017;66(8):1354-1355. doi:10.1136/gutjnl-2016-312529
 121. Dominguez-Munoz JE, Drewes AM, Lindkvist B, et al; HaPanEU/UEG Working Group. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. *Pancreatology*. 2018;18(8):847-854. doi:10.1016/j.pan.2018.09.016
 122. Rickels MR, Bellin M, Toledo FG, et al; PancreasFest Recommendation Conference Participants. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. *Pancreatology*. 2013;13(4):336-342. doi:10.1016/j.pan.2013.05.002
 123. Lévy P, Domínguez-Muñoz E, Imrie C, Löhr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. *United European Gastroenterol J*. 2014;2(5):345-354. doi:10.1177/2050640614548208
 124. Lowenfels AB, Maisonneuve P, Cavallini G, et al; International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. *N Engl J Med*. 1993;328(20):1433-1437. doi:10.1056/NEJM199305203282001
 125. Midha S, Sreenivas V, Kabra M, Chattopadhyay TK, Joshi YK, Garg PK. Genetically determined chronic pancreatitis but not alcoholic pancreatitis is a strong risk factor for pancreatic cancer. *Pancreas*. 2016;45(10):1478-1484. doi:10.1097/MPA.0000000000000684
 126. Shelton CA, Umapathy C, Stello K, Yadav D, Whitcomb DC. Hereditary pancreatitis in the United States: survival and rates of pancreatic cancer [Published online July 18, 2018]. *Am J Gastroenterol*. 2018;113(9):1376. doi:10.1038/s41395-018-0194-5